Cytex Therapeutics

What Cytex Therapeutics does

Cytex Therapeutics, Inc., operating as CytexOrtho, is a privately held, clinical-stage medical device company headquartered in Durham, North Carolina. The company is developing the ReNew Hip Implant, a bioabsorbable orthopedic device that integrates a high-performance 3D woven textile scaffold with a Tru3D printed component, manufactured from 100% bioabsorbable polycaprolactone (PCL). The implant is designed for patients aged 14-64 with early-stage hip osteoarthritis or femoral head cartilage loss, an underserved cohort considered too young for total hip replacement, and is intended to restore joint anatomy while supporting the body's own cartilage regeneration, leaving behind only natural tissue as the implant dissolves.

The underlying platform is anchored by proprietary 3D weaving technology that creates anisotropic scaffolds mimicking the mechanical properties of healthy articular cartilage, protected by 5 US patents and 14 international patents and documented in 20+ peer-reviewed publications. The company received FDA Breakthrough Device Designation in January 2023 on the basis of no approved alternatives, followed by FDA approval of its Phase I Investigational Device Exemption on October 29, 2024, enabling first-in-human enrollment of up to 15 patients at Washington University in St. Louis under principal investigators Dr. Jeff Nepple and Dr. John Clohisy. Future pivotal trials are planned to enroll 150-250 patients across multiple U.S. clinics as the company progresses toward Class III Premarket Approval (PMA).

CytexOrtho has no commercial revenue today and has been funded primarily through NIH and related federal grants, a successful equity crowdfunding round in 2023, and an ongoing bridge round of up to $3M in 2024. The go-to-market motion targets orthopedic surgeons at academic medical centers via enterprise field sales, with future revenue expected from one-time sales of implants to hospitals and orthopedic surgery centers following FDA approval. The company is led by co-founders Dr. Bradley Estes (CEO), Dr. Farshid Guilak (Executive Chairman), and Dr. Frank Moutos (VP of Technology), supported by fractional CFO and CSO executives with prior orthopedic industry experience at Medtronic, Smith & Nephew, and Zimmer Biomet.

Name

Cytex Therapeutics

Legal name

Cytex Therapeutics, Inc

Website

https://cytexortho.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

Cytex Therapeutics (DBA CytexOrtho) is a clinical-stage medical device company developing the ReNew Hip Implant, a 100% bioabsorbable 3D woven textile scaffold for cartilage repair in patients aged 14-64 with early-stage hip osteoarthritis who are too young for total hip replacement.

Ownership category

akta.pro rank

Product category

Orthopedic Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)

akta.pro secondary industries

3D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial) (HLAHAEAJ), Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB), Orthopedic Joint Reconstruction Implants (Hip/Knee/Shoulder/Elbow/Ankle) (HLAHAEAA)

Keywords

• Cartilage repair implants
• Orthopedic medical devices
• Tissue engineering scaffolds
• Bioabsorbable hip implants
• Joint preservation technology

Headquarters

HQ city

Durham

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Medical Device Sales: CytexOrtho is a clinical-stage medical device company developing the ReNew Hip Implant for cartilage repair. Revenue will be generated through the sale of medical implants to hospitals and orthopedic surgery centers following FDA approval. The company is currently conducting Phase I clinical trials.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels10 records

Core offering

CytexOrtho develops the ReNew Hip Implant, a bioabsorbable joint restoration device made from polycaprolactone (PCL) using proprietary 3D weaving technology integrated with Tru3D printed components. The implant is designed to restore joint anatomy, integrate with surrounding cartilage and bone, and support the body's own regenerative processes to regrow cartilage in patients with early hip osteoarthritis. The company is currently conducting Phase I clinical trials at Washington University in St. Louis under an FDA-approved IDE.

Product overview

CytexOrtho is developing a single flagship product: the ReNew™ Hip Implant, a novel cartilage repair implant that uses proprietary 3D weaving technology combined with Tru3D printing to create a bioabsorbable device. The implant is designed to restore joint anatomy and support natural tissue regeneration. The company is currently conducting Phase I clinical trials (IDE study approved by FDA in October 2024) at Washington University in St. Louis. All products are in development and not yet FDA approved or commercially available.

Differentiator

Problem solved

Functional benefit

Products and services

• ReNew™ Hip Implant A novel joint restoration implant created by integrating a high-performance 3D woven textile structure with a Tru3D printed component. The bioabsorbable device, made from polycaprolactone (PCL), is designed to restore joint anatomy, integrate with native tissues, and support the body's regenerative processes to regrow cartilage in patients with early hip osteoarthritis.

Quantifiable outcome

• Clinical trial will evaluate efficacy in improving pain and function over 12 months with 60-month follow-up
• +2 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered minor and core.

• MedTech InnovatorminorGTM or Marketing Partner · 6 May 2024CytexOrtho was selected as one of approximately 200 companies out of 1,400+ applicants to pitch at MedTech Innovator Road Show Events, with opportunity to meet investors, payers, providers, KOLs, regulatory agencies, and other medical technology experts.
• MCRAminorImplementation/ SI/ Consulting Partner · 9 February 2024MCRA (Medical Device Consultant Resource Association) served as organizer and judge for the inaugural AAOS OrthoPitch competition. Dave McGurl, VP of Orthopedic Regulatory Affairs at MCRA and former FDA acting branch Chief of Orthopedics, served as judge.
• Arthritis FoundationminorStrategic or Co-development Partner · 11 May 2023Hosted OA Innovation Shark Tank meeting at U.S. Congress on May 11th, 2023. Dr. Brad Estes sat on a panel about the state of osteoarthritis in the United States and the need for additional funding to move scientific advances to the clinic.
• Angry@ArthritisminorStrategic or Co-development Partner · 11 May 2023Collaborated with newly formed nonprofit Angry@Arthritis to host OA Innovation Shark Tank event at U.S. Congress to showcase promise of new cures and call for increased federal funding.
• Washington University School of MedicinecoreImplementation/ SI/ Consulting PartnerPrimary clinical trial site for the ReNew Hip implant. Dr. Jeff Nepple (Assistant Professor of Orthopedics) and Dr. John Clohisy serve as Principal Investigators conducting the Phase I clinical trial in St. Louis, MO.
• CED (Council for Entrepreneurial Development)minorGTM or Marketing PartnerOrganized Venture Connect 2024 event, now in its 40th year, facilitating connections and potential investor engagements for tech and biotech companies throughout the southeast.
• Duke UniversitycoreStrategic or Co-development PartnerDr. Farshid Guilak was formerly at Duke University where much of the foundational research was conducted. The company leverages pioneering tissue regeneration work developed at Duke. Dr. Brian Lau and Dr. Chad Mather from Duke serve on the Clinical Advisory Board.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Vericel Corporation: Vericel markets MACI, an autologous cultured chondrocyte implant for cartilage repair, making it a direct competitor in the orthopedic cartilage regeneration space. Both companies target joint preservation as an alternative to total joint replacement in younger, active patients.
• Anika Therapeutics: Anika Therapeutics develops hyaluronic acid-based cartilage repair and regenerative orthopedic products (e.g., Hyalofast, Cingal). Highlighted alongside CytexOrtho in the 2024 Bonezone regenerative medicine feature, both target cartilage restoration in osteoarthritis.
• Histogenics (now part of Ocugen): Histogenics developed NeoCart, a tissue-engineered cartilage implant for knee cartilage repair. Direct comparable as a tissue-engineering approach to cartilage regeneration in orthopedics.

Broad incumbents

• Stryker Corporation: Stryker is a global orthopedic medical device leader with hip and joint preservation products. Strategic acquirer of CytexOrtho board members' prior companies (Mobius Imaging, Cardan Robotics) for $500M aggregate; potential commercial partner or acquirer.
• Zimmer Biomet: Zimmer Biomet is a major orthopedic implant manufacturer with hip reconstruction and biologics portfolios. CytexOrtho board member Dave Nolan is a former Zimmer Biomet business development leader, reflecting close industry ties and potential strategic interest.
• Smith & Nephew: Smith & Nephew is a leading orthopedic and sports medicine company with hip and knee cartilage repair offerings including the Regeneten bioinductive implant. CytexOrtho's CSO previously held senior roles there.
• Medtronic: Medtronic's Spine and Biologics division develops regenerative and orthobiologic products. CytexOrtho CEO Brad Estes previously worked at Medtronic, making it a comparable large medtech with adjacent orthopedic interest.

Emerging players

• ConforMIS: ConforMIS develops patient-specific 3D-printed knee and hip implants. Comparable to CytexOrtho's use of Tru3D printing combined with engineered scaffolds to create custom-fit orthopedic implants for joint restoration.
• SurGenTec: SurGenTec is a regenerative medicine company featured alongside CytexOrtho in the 2024 Bonezone article on body-healing orthopedic technologies. Both companies are emerging players in biologics-driven orthopedic solutions.
• Orthocell Limited: Orthocell develops autologous cartilage and tendon regeneration therapies (e.g., Ortho-ATI, Ortho-ACI). Comparable as an emerging regenerative medicine company addressing cartilage repair in active patient populations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/CytexOrtho
• YouTubeyoutube.com/channel/UCqGnED0zEL6q5z2E7bY4cvw
• Facebookfacebook.com/cytexortho
• LinkedInlinkedin.com/company/cytex-therapeutics-inc.
• Instagraminstagram.com/cytexortho

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds21 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cytex Therapeutics